Download PDF
Hamostaseologie 2005; 25(02): 205-208
DOI: 10.1055/s-0037-1619656
Original Article
Schattauer GmbH

Leberzirrhose und Gerinnungsstörungen

Liver cirrhosis and coagulopathy
I. Scharrer
1   Hämostaseologie (Leiterin: Prof. Dr. med. Inge Scharrer), J.W. Goethe Universitätskliniken Frankfurt am Main
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Leberzirrhose ist häufig assoziiert mit komplexen Gerinnungsstörungen und einer Thrombozytopenie. Durch die verminderte Syntheseleistung tritt eine Vielzahl von Störungen auf, die eine sorgfältige Diagnose und gezielte Therapie auf der Intensivstation erfordern.

Summary

In patients with chronic liver disease profound coagulation changes and thrombocytopenia may lead to life-threatening bleeding that requires thorough diagnosis and immediate blood product replacement.

Schlüsselwörter

Leberzirrhose - Gerinungsstörungen - verminderte Syntheseleistung

Keywords

Cirrhosis - coagulopathy - impaired synthesis
 

  • Literatur

  • 1 Bernstein D. Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced child’s B and C cirrhosis. Semin Thromb Hemost 2000; 26: 437-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Bizollon T. Fibrinolytic therapy for portal vein thrombosis. Lancet 1991; 337: 1416.
    PubMedGoogle Scholar
  • 3 Bravo AA, Seth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
    CrossrefPubMedGoogle Scholar
  • 4 Carmassi F, Morale M, DeNegri F. et al. Modulation of hemostatic balance with antithrombin replacement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis. J Mol Med 1995; 73: 89-93.
    CrossrefPubMedGoogle Scholar
  • 5 Carr JM. Disseminated intravascular coagulation in cirrhosis. Hepatology 1989; 10: 103-10.
    CrossrefPubMedGoogle Scholar
  • 6 Chan V, Lai CL, Chan TK. Metabolism of antithrombin III in cirrhosis and cancer of the liver. Clin Sci 1981; 60: 681-8.
    CrossrefPubMedGoogle Scholar
  • 7 Child CG, Turcotte JG. Surgery and Portal Hypertension. Philadelphia: Saunders; 1964: 50-64.
    Google Scholar
  • 8 Condat B, Pessione F, Hillaire S. et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120: 490-7.
    CrossrefPubMedGoogle Scholar
  • 9 DeCaterina MI, Tarantino G, Farina C. Haemostasis unbalance in Pugh-scored liver cirrhosis; characteristic changes of plasma levels of protein C versus protein S. Haemostasis 1993; 23: 229-35.
    PubMedGoogle Scholar
  • 10 Denninger MH, Chait Y, Casadevall N. et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587-91.
    CrossrefPubMedGoogle Scholar
  • 11 Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982; 35: 667-72.
    CrossrefPubMedGoogle Scholar
  • 12 Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of γ-carboxyglutamic acid. Blood 1999; 93: 1798-808.
    PubMedGoogle Scholar
  • 13 Green AJ, Ratnoff OD. Elevated antihemophilic factor (AHF, factor VIII) procoagulant activity and AHF like antigen in alcoholic cirrhosis of the liver. J Lab Clin Med 1974; 83: 189-97.
    PubMedGoogle Scholar
  • 14 Hu KQ, Yu AS, Tiyyagura L. et al. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96: 1581-6.
    CrossrefPubMedGoogle Scholar
  • 15 Izumi S, Langley PG, Wendon J. et al. Coagulation factor V levels as a prognostic indicator or in fulminant hepatic failure. Hepatology 1996; 23: 1507-11.
    CrossrefPubMedGoogle Scholar
  • 16 Köhler M, Hellstern P, Lechler E. et al. Thromboembolic complications associated with the use of prothrombin complex an factor IX concentrates. Thromb Haemost 1998; 80: 395-402.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Mammen EF. Coagulopathies of liver disease. Clin lab Med 1994; 14: 769-80.
    CrossrefPubMedGoogle Scholar
  • 18 Mann O, Haag K, Hauenstein KH. et al. Septische Pfortaderthrombose. Dtsch Med Wochenschr 1995; 120: 1201-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Mannucci PM, Vicente V, Vianello L. Controlled trial of desmopressin in liver cirrhosis and other bleeding time. Blood 1986; 67: 1148.
    CrossrefPubMedGoogle Scholar
  • 20 Paramo JA, Rocha E. Hemostasis in advanced liver disease. Sem Thromb Hemost 1993; 19: 184-90.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Pugh RNH, Muray-Lyon IM, Dawson JL. et al. Transection of the esophagus in the bleeding esophageal varices. Br J Surg 1973; 60: 648-52.
    PubMedGoogle Scholar
  • 22 Rapaport SI. Coagulation problems in liver disease. Blood Coagul Fibrinol 2000; 11: 69-74.
    CrossrefPubMedGoogle Scholar
  • 23 Scharrer I, Encke A, Hottenrott C. Clinical cure of haemophilia A by liver transplantation. Lancet 1988; I: 800-1.
    PubMedGoogle Scholar
  • 24 Vigano S, Mannucci PM, D’Angelo A. et al. The significance of protein C antigen in acute and chronic liver biliary disease. Am J Clin Pathol 1985; 84: 454-8.
    CrossrefPubMedGoogle Scholar
  • 25 Violi F, Ferro D, Basili S. et al. Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J Invest Med 1995a 43: 550-4.
    PubMedGoogle Scholar
  • 26 Violi F, Ferro D, Basili S. et al. Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. Hepatology 1995b 22: 96-100.
    PubMedGoogle Scholar